Products for Research Use Only
RegisterLogin

Celgosivir

CAT: 0804-HY-16134-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16134-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Celgosivir (MBI 3253; MDL 28574; MX3253) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
CAS Number
121104-96-9
Product Name Alternative
MBI 3253; MDL 28574; MX3253
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Dengue Virus; Flavivirus; Glycosidase; HCV; HIV
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Celgosivir.html
Solubility
10 mM in DMSO
Smiles
O[C@@H]1[C@]2([H])[C@@H](O)[C@H](O)[C@@H](OC(CCC)=O)CN2CC1
Molecular Formula
C12H21NO5
Molecular Weight
259.30
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Taylor DL, et al. Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoylcastanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother. 1994 Aug;38 (8) :1780-7.|[2]Whitby K, et al. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother. 2004 May;15 (3) :141-51.|[3]Watanabe S, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012 Oct;96 (1) :32-5.|[4]Rathore AP, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes andprotects against lethal challenge mouse model. Antiviral Res. 2011 Dec;92 (3) :453-60.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HIV-1
Citation 01
University of Pennsylvania. 2018 Dec.|J Virol. 2025 Mar 18;99 (3) :e0001825.

Alternative Products

CatalogName
TRC-C256505-100MGCelgosivir
A13118-1Celgosivir 1mg
A13118-25Celgosivir 25mg
A13118-5Celgosivir 5mg
A13118-2Celgosivir 2mg
CS-O-43560Celgosivir hydrochloride
A13118-100Celgosivir 100mg
A13118-500Celgosivir 500mg
A13118-50Celgosivir 50mg
A13118-10Celgosivir 10mg

Popular Products